PRESS RELEASE

annai_logo_alternate-notagline-webCARLSBAD, CA – June 28, 2016 – Annai Systems, a leading genomic data solutions company, today announced it will provide its STARPlatform next-generation sequencing data management solution to the Glioma Longitudinal AnalySiS (GLASS) consortium. The GLASS consortium consists of neuropathologists, clinicians, scientists, and bioinformaticians from leading institutions across the globe. Annai Systems’ STARPlatform will enable GLASS to manage whole exome and genome sequencing data across multiple research centers.

“We’re excited to announce that the GLASS consortium is adopting STARPlatform,” said Michael Penley, Annai Systems’ CEO. “We’re honored to partner with GLASS and provide our services to help them lead the charge in glioma tumor research. We developed our solutions to address the full range of needs for next-generation genomics research, from the individual researcher to large-scale consortia.”

GLASS aims to accelerate efforts to understand glioma tumor evolution and identify new ways to treat the tumors. The consortium was awarded a substantial grant by the National Brain Tumor Society earlier this year. The organizations spearheading the consortium include the University of Texas MD Anderson Cancer Center, University of California, San Francisco and the Samsung Medical Center.

“The GLASS consortium is focused on further understanding glioma tumors to help usher in more effective therapies to patients, and using the leading data technologies is a critical component of our daily operations,” said Roel Verhaak, Ph.D., GLASS’ lead investigator and assistant professor of bioinformatics and computational biology at the University of Texas MD Anderson Cancer Center. “STARPlatform provides a secure, collaborative workspace to normalize and share data, which is exceptionally important to us. Annai has one of the most innovative solutions in the industry that offers the functionality we need.”

Annai Systems will be discussing the benefits of STARPlatform today, June 28th, at 10:30 AM EDT at the Festival of Genomics in Boston on the Clinical Stage.

About Annai Systems

Annai Systems is a leading genomic data analysis company committed to developing cost-reducing innovations that accelerate scientific discovery, maximize statistical power, and optimize data control. From data compression and storage to secondary and tertiary analysis, the company offers a true end-to-end solution designed to handle the complex needs of next-generation sequencing data in the clinical, pharmaceutical and research environments. Annai Systems’ flagship product, STARPlatform, enables researchers to innovate, collaborate, and make new discoveries – all in less time and at lower costs than traditional solutions. For more about Annai Systems, visit www.annaisystems.com or follow us on Twitter, Facebook and LinkedIn.

About the GLASS Consortium

The Glioma Longitudinal AnalySiS (GLASS) consortium comprising neuropathologists, clinicians, scientists, and bioinformaticians from leading institutions across the globe was recently inaugurated to accelerate efforts to (1) understand glioma tumor evolution and (2) expose therapeutic vulnerabilities. The GLASS consortium intends to generate a longitudinal genomic/molecular dataset representing a large cohort of glioma patients across 3 specified diffuse glioma genomic subtypes: IDH-wild-type, IDH-mutant, and IDH-mutant 1p/19q co-deletion. These initiatives have the potential to identify practice-changing new insights and will provide a useful reference dataset to the glioma community. Learn more about the GLASS consortium at www.glass-consortium.org.